Neurovision Receives Financing for Retinal Imaging Technology

Imaging and diagnostic solutions provider Neurovision Imaging LLC has raised financing for regulatory approval of its retinal imaging technology for the early detection and monitoring of Alzheimer’s-related amyloid pathology.

The company’s imaging technology focuses on the retina, a developmental outgrowth of the central nervous system sharing many of the brain's characteristics, enabling the potential of retinal imaging for amyloid detection in Alzheimer's disease.

The Series B financing was led by a $5 million investment from Wildcat Capital Management. A portion of the funds is being reserved for strategic investors.

Leonard Potter, chief investment officer and president of Wildcat Capital Management, has been named to Neurovision’s board of directors.